| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/14/2007 | CN1911438A 血管新生诱导剂 Angiogenic inducer |
| 02/14/2007 | CN1911397A Method for lowering fat and weight-reducing by using ion-guiding of traditional Chinese medicine |
| 02/14/2007 | CN1911350A Chinese and western medicine composition contg. metformin |
| 02/14/2007 | CN1911349A Medicine composition for treating diabetes |
| 02/14/2007 | CN1911348A Chinese and western medicines composition contg. Avandia and its prepn. method |
| 02/14/2007 | CN1911334A Traditional Chinese medicine composition for lowering blood fat, and prepn. method therefor |
| 02/14/2007 | CN1911326A Oral medicine contg. donkey-hide gelatin and iron, and its prepn. method |
| 02/14/2007 | CN1911297A Novel clinic use of Naoxueshuan capasule for treating cerebral thrombosis |
| 02/14/2007 | CN1911289A Compound medicine contg. musk |
| 02/14/2007 | CN1911251A Traditional Chinese medicine enteric oral liquor using fresh earthworm extractive as active component, and its prepn. method |
| 02/14/2007 | CN1911245A Metal compunds, mixed or sulphated, as phosphate binders |
| 02/14/2007 | CN1911244A Slow-released type iron-complement agent, prepn. method and use thereof |
| 02/14/2007 | CN1911241A Slow-released type iodine complement agent, and prepn. method and use-thereof |
| 02/14/2007 | CN1911239A Selenium-complement agent, and prepn. method and use thereof |
| 02/14/2007 | CN1911221A Use of a hypoglycemic agent for treating impaired glucose metabolism |
| 02/14/2007 | CN1911220A Injection contg. seven vitamins and taurine |
| 02/14/2007 | CN1911213A Soft capsule of atovastatine salts and prepn. method therefor |
| 02/14/2007 | CN1911209A Quick-disintegration tablets of calcium atovastatine, and its prepn. method |
| 02/14/2007 | CN1300173C Human antibodies that bind huma TNF 'alpha' |
| 02/14/2007 | CN1300155C Clycerophosphoinositol derivatives as modulators of cytosolic phospholipase |
| 02/14/2007 | CN1299742C Medicine for treating diabetes, and its prepn. method |
| 02/14/2007 | CN1299733C Chinese medicine and its preparing method and use |
| 02/14/2007 | CN1299715C Preparing tablets of reducing blood fat |
| 02/14/2007 | CN1299689C Application of alendronate in preparation of drug for inhibitting bone resorption |
| 02/14/2007 | CN1299688C Amino acid liquor and its preparation method |
| 02/14/2007 | CN1299683C Celecoxib compositions |
| 02/14/2007 | CN1299602C Nutritive food capable of regulating blood sugar |
| 02/13/2007 | US7176229 Pyrrolidine antiinflammatory agents for rheumatoid arthritis, osteoarthritis; antiallergens for asthma, chronic bronchitis, allergic rhinitis, adult respiratory distress syndrome, chronic pulmonary inflammatory disease; reduce or eliminate adverse CNS side effects associated with prior PDE4 inhibitors |
| 02/13/2007 | US7176224 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists |
| 02/13/2007 | US7176215 Bicyclic oxopyridine and oxopyrimidine derivatives |
| 02/13/2007 | US7176213 For example, 1-(9-benzylamino-10-cyano-imidazo[1,2-a]quinolin-2-carbonyl)pyrrolidine; may be used for the treatment of diseases such as asthma, glaucoma, tumors, allergic and inflammatory diseases, ischemia, hypoxia, arrythmia and renal diseases |
| 02/13/2007 | US7176210 Cannabinoid receptor ligands and uses thereof |
| 02/13/2007 | US7176204 Substituted carboxylic acid derivatives |
| 02/13/2007 | US7176194 Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| 02/13/2007 | US7176193 Antilipemic agents; therapy for insulin resistance |
| 02/13/2007 | US7175849 Polypeptide for use in the treatment of viral disorders |
| 02/13/2007 | CA2361288C Mutual prodrug of amlodipine and atorvastatin |
| 02/13/2007 | CA2358840C Methods and kits comprising an estrogen agonist/antagonist for improving vascular health |
| 02/13/2007 | CA2266378C Use of sibutramine analogues to lower lipid levels |
| 02/13/2007 | CA2219947C Monoclonal antibody reactive to human cetp and assay method for human cetp |
| 02/12/2007 | CA2553115A1 Modulation of peroxisome proliferation-activated receptors |
| 02/09/2007 | CA2554969A1 Chemoprotectants from crucifer seeds and sprouts |
| 02/08/2007 | WO2007016600A2 Method of preserving the function of insulin-producing cells |
| 02/08/2007 | WO2007016353A2 Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists |
| 02/08/2007 | WO2007016108A1 Compositions for affecting weight loss |
| 02/08/2007 | WO2007015807A1 Phenyl compounds |
| 02/08/2007 | WO2007015767A1 Pyridine derivatives as dipeptedyl peptidase inhibitors |
| 02/08/2007 | WO2007015585A1 Agent for reduction of oxidized albumin level |
| 02/08/2007 | WO2007015162A1 Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds |
| 02/08/2007 | WO2007015161A1 Novel substituted azetidinones |
| 02/08/2007 | WO2007015069A2 Compositions for ameliorating a reduced higher brain function resulting from organic brain lesions |
| 02/08/2007 | WO2007015003A2 Novel crystalline iii form of agomelatine, method of the preparation thereof and pharmaceutical compositions containing said form |
| 02/08/2007 | WO2007015002A2 Novel crystalline iv form of agomelatine, method of the preparation thereof and pharmaceutical compositions containing said form |
| 02/08/2007 | WO2007014929A1 Use of flibanserin in the treatment of obesity |
| 02/08/2007 | WO2007014895A2 Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives |
| 02/08/2007 | WO2007014886A1 Hydrochlorides and hydrates of 1-[(3-cyanopyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-aminopiperidin-1-yl)xanthine, their preparation and their use as medicaments |
| 02/08/2007 | WO2007014619A1 Novelimidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same |
| 02/08/2007 | WO2006110477A3 Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus |
| 02/08/2007 | WO2006088875A3 Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels |
| 02/08/2007 | WO2006077442A3 Inhibition of islet amyloid polypeptide (iapp) aggregation for the treatment of type 2 diabetes |
| 02/08/2007 | WO2006055526B1 Compositions useful to treat ocular neovascular diseases and macular degeneration |
| 02/08/2007 | WO2005107728A3 Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity |
| 02/08/2007 | US20070032653 N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. |
| 02/08/2007 | US20070032643 Cis-element regulating transcription, transcriptional regulatory factor binding specifically thereto and use of the same |
| 02/08/2007 | US20070032642 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 02/08/2007 | US20070032538 Use of compounds |
| 02/08/2007 | US20070032537 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases |
| 02/08/2007 | US20070032521 Use of c-kit inhibitors for treating type II diabetes |
| 02/08/2007 | US20070032520 Indol-5-yl sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 02/08/2007 | US20070032518 Compounds and methods of use |
| 02/08/2007 | US20070032507 Treatment of diseases or disorders mediated by T lymphocytes and/or PKC; may be coadminstered with an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug. |
| 02/08/2007 | US20070032498 Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species |
| 02/08/2007 | US20070032487 Inhibitors of phosphatidylinositol 3-kinase |
| 02/08/2007 | US20070032474 Use of a compound of formula 1 for making a pharmaceutical composition |
| 02/08/2007 | US20070032466 Drug containing chymase inhibitor as the active ingredient |
| 02/08/2007 | US20070032463 Drug, foods or drinks for ameliorating hyperglycemia |
| 02/08/2007 | US20070031979 Protein biopolymer markers predictive of type II diabetes |
| 02/08/2007 | US20070031965 Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain; use in preventing or treating a pathogen infection in a cell or organism |
| 02/08/2007 | US20070031945 High mannose proteins and methods of making high mannose proteins |
| 02/08/2007 | US20070031860 G-protein coupled receptor and uses therefor |
| 02/08/2007 | US20070031570 Hydrothermically processed compositions containing phytosterols |
| 02/08/2007 | US20070031523 purified plant extract for treating menopausal-syndrome; no side effect; ameliorating ovary function and regulating estrogen and progestogen, prevent many diseases due to imbalance of estrogen and progestrogen; for patients which need to use estrogen but with contraindication of hormone |
| 02/08/2007 | US20070031493 Pharmaceutical compositions |
| 02/08/2007 | US20070031443 Methods for treating or preventing skin disorders using CD2-binding agents |
| 02/08/2007 | US20070029259 Method of reducing impurity content in aqueous salt solution |
| 02/08/2007 | DE202006014910U1 Agent, useful for fat reduction, comprises polyethylene and polyisobutylene |
| 02/08/2007 | CA2617654A1 Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds |
| 02/08/2007 | CA2617546A1 Use of flibanserin in the treatment of obesity |
| 02/08/2007 | CA2617282A1 Novel imidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same |
| 02/08/2007 | CA2617226A1 Method of preserving the function of insulin-producing cells |
| 02/08/2007 | CA2617150A1 Use of chk2 kinase inhibitors for cancer treatment |
| 02/08/2007 | CA2617102A1 Substituted tetrahydro-1h-pyrido[4,3,b]indoles as serotonin receptor agonists and antagonists |
| 02/08/2007 | CA2617090A1 Hydrochlorides and hydrates of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methy l-7-(2-butyn-1-yl)-8-(3-amino-piperidin-1-yl)xanthine,their preparation and their use as medicaments |
| 02/08/2007 | CA2616702A1 Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives |
| 02/08/2007 | CA2615758A1 Novel substituted azetidinones |
| 02/08/2007 | CA2614539A1 Compositions for affecting weight loss |
| 02/07/2007 | EP1749886A2 Polypeptides having kinase activity, their preparation and use |
| 02/07/2007 | EP1749819A1 (rac)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide hydrates |
| 02/07/2007 | EP1749539A2 Preventives or remedies for fatty liver |
| 02/07/2007 | EP1749534A2 Use of parasitic biological agents for prevention and control of autoimmune diseases |